Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine : Second interim analysis of data from a phase III, multi-institutional trial

• Published in: Annals of surgery 1997-08, Vol.226 (2), p.198-206
• Main Authors: WALLACK, M. K, SIVANANDHAM, M, RICHARDS, J. M, ROSEN, L, BARTOLUCCI, A. A, DITARANTO, K, SHAW, P, BALCH, C. M, URIST, M. M, BLAND, K. I, MURRAY, D, ROBINSON, W. A, FLAHERTY, L
• Format: Article
• Language: English
• Subjects: Adult; Antineoplastic agents; Biological and medical sciences; Cancer Vaccines; Combined treatments (chemotherapy of immunotherapy associated with an other treatment); Disease-Free Survival; Female; Humans; Immunotherapy, Adoptive; Male; Medical sciences; Melanoma - mortality; Melanoma - therapy; Middle Aged; Pharmacology. Drug treatments; Prospective Studies; Skin Neoplasms - mortality; Skin Neoplasms - therapy; Smallpox Vaccine - therapeutic use; Survival Rate; Vaccines
• ISSN: 0003-4932; 1528-1140
• DOI: 10.1097/00000658-199708000-00012

The efficacy of vaccinia melanoma oncolysate (VMO) vaccine to increase overall survival and disease-free survival of patients with surgically resected International Union Against Cancer (UICC) stage II melanoma was studied in a phase III, randomized, multi-institutional trial. Phase I and II trials with VMO showed minimal toxicity and clinical efficacy in patients with melanoma. In a recently completed phase III VMO trial, the first interim analysis performed in April 1994 showed an increasing trend in the survival of patients treated with VMO. The second interim analysis was performed in April 1995. Patients with surgically resected stage II (UICC) melanoma were treated with VMO (N = 104) or placebo vaccinia vaccine virus (V) (N = 113) once a week for 13 weeks and then once every 2 weeks for a total of 12 months. Patients' clinical data were collected as of May 1995 and analyzed for survival. In this second interim analysis, the mean follow-up time is 42.28 months. No survival difference was observed between VMO and V treatments. However, in a retrospective subset analysis, a subset of males between the ages of 44 and 57 years and having one to five positive nodes (at 2-, 3-, and 5-year intervals, 13.6%, 15.9%, and 20.3% difference insurvival in favor of VMO [N = 20] when compared to V [N = 18] [p = 0.037]) and another subset of patients with clinical stage I (at 3- and 5-year intervals, 30% and 7% difference in survival in favor of VMO [N = 20] when compared to V [N = 23], [p = 0.05]) showed significant survival advantage with VMO. Although VMO vaccine therapy in surgical adjuvant setting did not produce a significant survival benefit to all patients with melanoma, patients from the above two subsets had significant survival benefit.